Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 7/20 | 0.41 |
| ▸ | CTSK | P43235 | 7/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2550395 | 0.89 | ATM (0.48) | ATMAAK1TSHRCTSLTACR1 | |
| SCHEMBL2550398 | 0.89 | ATM (0.48) | ATMAAK1TSHRCTSLTACR1 | |
| SCHEMBL740615 | 0.86 | ATM (0.49) | ATMAAK1TSHRCTSLTACR1 | |
| SCHEMBL1519890 | 0.86 | ATM (0.49) | ATMAAK1TSHRCTSLTACR1 | |
| SCHEMBL740616 | 0.86 | ATM (0.49) | ATMAAK1TSHRCTSLTACR1 | |
| SCHEMBL5757441 | 0.86 | ATM (0.53) | ATMAAK1CTSLCTSSCTSK | |
| SCHEMBL27228862 | 0.85 | ATM (0.46) | ATMAAK1TSHRCTSLTACR1 | |
| SCHEMBL27232277 | 0.85 | ATM (0.46) | ATMAAK1TSHRCTSLTACR1 | |
| SCHEMBL27228856 | 0.85 | ATM (0.46) | ATMAAK1TSHRCTSLTACR1 | |
| SCHEMBL6008671 | 0.84 | CTSL (0.60) | ATMAAK1CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078537-B2 | Phenylalkyl diamine and amide analogs | SK CORPORATION (KR) | 2006-07-18 | — | — | US | disclosed |
| EP-1401821-A4 | NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS | SK CORP (KR) | 2006-05-31 | — | — | EP | disclosed |
| EP-1401821-A1 | NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS | SK Corporation (KR) | 2004-03-31 | — | — | EP | disclosed |
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2003-06-05 | — | — | US | disclosed |
| WO-2002100848-A1 | NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS | SK CORPORATION (KR) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SIGMAR1, TAAR1, OPRL1 | ATM 3190/4885AAK1 726/4885TSHR 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.